Document is current
Any future updates will be listed below
-
Authors
Doane, Ashley S. http://orcid.org/0000-0002-1489-1786
Chu, Chi-Shuen
Di Giammartino, Dafne Campigli
Rivas, MartÃn A. http://orcid.org/0000-0002-9603-6897
Hellmuth, Johannes C.
Jiang, Yanwen
Yusufova, Nevin
Alonso, Alicia
Roeder, Robert G.
Apostolou, Effie
Melnick, Ari M. http://orcid.org/0000-0002-8074-2287
Elemento, Olivier http://orcid.org/0000-0002-8061-9617
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (1F31CA220981-01)
- License Information
-
More Information
Article History
Received: 30 September 2020
Accepted: 5 August 2021
First Online: 23 September 2021
Competing interests
: A.M.M. receives research funding from Janssen and Daiichi Sankyo, has consulted for Constellation, Jubilant and Epizyme, and is on the advisory board of KDAC. O.E. is scientific advisor and equity holder in Freenome, Owkin, Volastra Therapeutics and OneThree Biotech. A.S.D., C.-S.C., D.C.D.G., M.A.R., J.C.H., Y.J., N.Y., A.A., R.G.R. and E.A. declare no competing interests.
